Xilio Therapeutics Inc (NASDAQ: XLO) is -10.99% lower on its value in year-to-date trading and has touched a low of $0.62 and a high of $1.70 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The XLO stock was last observed hovering at around $1.15 in the last trading session, with the day’s loss setting it -0.3%.
Currently trading at $0.85, the stock is 8.51% and 10.40% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.75 million and changing -26.09% at the moment leaves the stock -4.40% off its SMA200. XLO registered -27.97% loss for a year compared to 6-month loss of -14.15%.
The stock witnessed a 18.98% gain in the last 1 month and extending the period to 3 months gives it a -42.57%, and is 27.53% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 17.70% over the week and 9.88% over the month.
Xilio Therapeutics Inc (XLO) has around 64 employees, a market worth around $44.02M and $9.27M in sales. Profit margin for the company is -585.54%. Distance from 52-week low is 37.10% and -50.00% from its 52-week high. The company has generated returns on investments over the last 12 months (-313.20%).
The EPS is expected to grow by 44.04% this year
The shares outstanding are 51.78M, and float is at 16.42M with Short Float at 2.14%.
The top institutional shareholder in the company is BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC with over 3.79 million shares valued at $3.59 million. The investor’s holdings represent 13.5618 of the XLO Shares outstanding. As of 2024-06-30, the second largest holder is ROCK SPRINGS CAPITAL MANAGEMENT LP with 3.0 million shares valued at $2.85 million to account for 10.7595 of the shares outstanding. The other top investors are RIVERVEST VENTURE MANAGEMENT LLC which holds 1.44 million shares representing 5.1641 and valued at over $1.37 million, while FMR LLC holds 5.0008 of the shares totaling 1.4 million with a market value of $1.32 million.
Xilio Therapeutics Inc (XLO) Insider Activity
The most recent transaction is an insider sale by Frankenfield Christopher James, the company’s Chief Financial Officer. SEC filings show that Frankenfield Christopher James sold 6,954 shares of the company’s common stock on Jan 02 ’25 at a price of $0.98 per share for a total of $6841.0. Following the sale, the insider now owns 12421.0 shares.
Xilio Therapeutics Inc disclosed in a document filed with the SEC on Jan 02 ’25 that Brennan Kevin M. (SVP, FINANCE AND ACCOUNTING) sold a total of 1,803 shares of the company’s common stock. The trade occurred on Jan 02 ’25 and was made at $0.98 per share for $1774.0. Following the transaction, the insider now directly holds 3197.0 shares of the XLO stock.
Still, SEC filings show that on Dec 18 ’24, GILEAD SCIENCES, INC. (10% Owner) acquired 1,759,978 shares at an average price of $1.04 for $1.83 million. The insider now directly holds 9,105,451 shares of Xilio Therapeutics Inc (XLO).
